The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications

Journal of Cardiology

Volumn 59, Issue 3, 2012, Pages 235-242

  Puddu, Paolo ^a   Puddu, Giovanni M ^a   Cravero, Eleonora ^a   Vizioli, Luca ^a   Muscari, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allopurinol; Atherosclerosis; Oxidative stress; Risk factors; Uric acid; Xanthine oxidoreductase

Indexed keywords

ALLOPURINOL; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OXIPURINOL; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; XANTHINE OXIDASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GOUT; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY ISCHEMIA; LEUKOCYTE; LIVER ISCHEMIA; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SHOCK; STROKE;

ALLOPURINOL; ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERURICEMIA; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; OXYPURINOL; REACTIVE OXYGEN SPECIES; RISK FACTORS; URIC ACID; XANTHINE DEHYDROGENASE;

EID: 84860470278     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.01.013     Document Type: Review

References (112)

1. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress. Curr Pharm Des 2005, 11:4145-4151.
2. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
3. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78:6858-6862.
4. Lippi G., Montagnana M., Franchini M., Favaloro E.J., Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008, 392:1-7.
5. Viazzi F., Leoncini G., Ratto E., Pontremoli R. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. J Clin Hypertens (Greenwich) 2006, 8:510-518.
6. Neogi T., Terkeltaub R., Ellison R.C., Hunt S., Zhang Y. Serum urate is not associated with coronary artery calcification: the NHLBI Family Heart Study. J Rheumatol 2011, 38:111-117.
7. Krishnan E., Pandya B.J., Chung L., Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther 2011, 13:R66.
8. Puddu P., Puddu G.M., Cravero E., Rosati M., Muscari A. The molecular sources of reactive oxygen species in hypertension. Blood Press 2008, 17:70-77.
9. Stocker R., Keaney J.F. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005, 3:1825-1834.
10. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546-2551.
11. Meneshian A., Bulkley G.B. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 2002, 9:161-175.
12. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004, 555:589-606.
13. George J., Struthers A.D. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009, 5:265-272.
14. Galbusera C., Orth P., Fedida D., Spector T. Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 2006, 71:1747-1752.
15. Sanders S.A., Eisenthal R., Harrison R. NADH oxidase activity of human xanthine oxidoreductase-generation of superoxide anion. Eur J Biochem 1997, 245:541-548.
16. Harris C.M., Massey V. The reaction of reduced xanthine dehydrogenase with molecular oxygen. Reaction kinetics and measurement of superoxide radical. J Biol Chem 1997, 272:8370-8379.
17. Hille R. Molybdenum-containing hydroxylases. Arch Biochem Biophys 2005, 433:107-116.
18. Massey V., Harris C.M. Milk xanthine oxidoreductase: the first one hundred years. Biochem Soc Trans 1997, 25:750-755.
19. Bray R.C. The enzymes. Part XII 1975, Academic Press, New York, p. 303-87.
20. Duncan J.G., Ravi R., Stull L.B., Murphy A.M. Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H1512-H1518.
21. Stull L.B., Leppo M.K., Szweda L., Gao W.D., Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004, 95:1005-1011.
22. Doehner W., Anker S.D. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?. Heart 2005, 91:707-709.
23. Kittleson M.M., Hare J.M. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J 2005, 26:1458-1460.
24. Godber B.L., Doel J.J., Sapkota G.P., Blake D.R., Stevens C.R., Eisenthal R., Harrison R. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem 2000, 275:7757-7763.
25. Millar T.M., Stevens C.R., Benjamin N., Eisenthal R., Harrison R., Blake D.R. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 1998, 427:225-228.
26. Li H., Samouilov A., Liu X., Zweier J.L. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 2003, 42:1150-1159.
27. Kand'ar R., Zakova P., Muzakova V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta 2006, 365:249-256.
28. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005, 70:343-354.
29. Robinson K.M., Morre J.T., Beckman J.S. Triuret: a novel product of peroxynitrite-mediated oxidation of urate. Arch Biochem Biophys 2004, 423:213-217.
30. Szabó C., Ischiropoulos H., Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007, 6:662-680.
31. Pacher P., Schulz R., Liaudet L., Szabó C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 2005, 26:302-310.
32. Flesch M., Kilter H., Cremers B., Laufs U., Südkamp M., Ortmann M., Müller F.U., Böhm M. Effects of endotoxin on human myocardial contractility involvement of NO and peroxynitrite. J Am Coll Cardiol 1996, 33:1062-1070.
33. 2+-ATPase in human heart failure. Circulation 2005, 111:988-995.
34. Linke A., Adams V., Schulze P.C., Erbs S., Gielen S., Fiehn E., Möbius-Winkler S., Schubert A., Schuler G., Hambrecht R. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005, 111:1763-1770.
35. Hunt M.J., Aru G.M., Hayden M.R., Moore C.K., Hoit B.D., Tyagi S.C. Induction of oxidative stress and disintegrin metalloproteinase in human heart endstage failure. Am J Physiol Lung Cell Mol Physiol 2002, 283:L239-L245.
36. Levrand S., Vannay-Bouchiche C., Pesse B., Pacher P., Feihl F., Waeber B., Liaudet L. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 2006, 41:886-895.
37. Radi R., Peluffo G., Alvarez M.N., Naviliat M., Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001, 30:463-488.
38. Hink H.U., Santanam N., Dikalov S., McCann L., Nguyen A.D., Parthasarathy S., Harrison D.G., Fukai T. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002, 22:1402-1408.
39. Nozik-Grayck E., Suliman H.B., Piantadosi C.A. Extracellular superoxide dismutase. Int J Biochem Cell Biol 2005, 37:2466-2471.
40. Skinner K.A., White C.R., Patel R., Tan S., Barnes S., Kirk M., Darley-Usmar V., Parks D.A. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 1998, 273:24491-24497.
41. Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide 2007, 16:266-273.
42. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
43. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., Krotova K., Block E.R., Prabhakar S., Johnson R.J. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
44. Sánchez-Lozada L.G., Tapia E., López-Molina R., Nepomuceno T., Soto V., Avila-Casado C., Nakagawa T., Johnson R.J., Herrera-Acosta J., Franco M. Effects of acute and chronic l-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 2007, 292:F1238-F1244.
45. Gersch C., Palii S.P., Kim K.M., Angerhofer A., Johnson R.J., Henderson G.N. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008, 27:967-978.
46. Gersch C., Palii S.P., Imaram W., Kim K.M., Karumanchi S.A., Angerhofer A., Johnson R.J., Henderson G.N. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 2009, 28:118-149.
47. Imaram W., Gersch C., Kim K.M., Johnson R.J., Henderson G.N., Angerhofer A. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med 2010, 49:275-281.
48. Squadrito G.L., Cueto R., Splenser A.E., Valavanidis A., Zhang H.W., Uppu R.M., Pryor W.A. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000, 376:333-337.
49. VasquezVivar J., Santos A.M., Junqueira V.B.C., Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J 1996, 314:869-876.
50. Santos C.X.C., Anjos E.I., Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 1999, 372:285-294.
51. Yamaguchi Y., Matsuno S., Kagota S., Haginaka J., Kunitomo M. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis 2004, 172:259-265.
52. Kim K.M., Henderson G.N., Frye R.F., Galloway C.D., Brown N.J., Segal M.S., Imaram W., Angerhofer A., Johnson R.J. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:65-70.
53. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., Lauretani F., Bandinelli S., Senin U., Ferrucci L. Uric acid inflammatory markers. Eur Heart J 2006, 27:1174-1181.
54. Ferrucci L., Corsi A., Lauretani F., Bandinelli S., Bartali B., Taub D.D., Guralnik J.M., Longo D.L. The origins of age-related proinflammatory state. Blood 2005, 105:2294-2299.
55. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
56. Cheng T.H., Lin J.W., Chao H.H., Chen Y.L., Chen C.H., Chan P., Liu J.C. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2010, 139:42-49.
57. Liu L., Inoue H., Nakayama H., Kanno R., Kanno M. The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. Pathobiology 2007, 74:177-185.
58. Pechman K.R., Basile D.P., Lund H., Mattson D.L. Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2008, 294:1234-1239.
59. Corry D.B., Eslami P., Yamamoto K., Nyby M.D., Makino H., Tuck M.L. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
60. Price K.L., Sautin Y.Y., Long D.A., Zhang L., Miyazaki H., Mu W., Endou H., Johnson R.J. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006, 17:1791-1795.
61. Kanellis J., Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25:39-42.
62. Mankovsky B., Kurashvili R., Sadikot S. Is serum uric acid a risk factor for atherosclerotic cardiovascular disease? A review of the clinical evidence. Part 1, diabetes and metabolic syndrome. Clin Res Rev 2010, 4:176-184.
63. Woo J., Swaminathan R., Cockram C., Lau E., Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994, 70:486-491.
64. Liese A., Hense H., Lowel H., Doring A., Tietze M., Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999, 10:391-397.
65. Fang J., Alderman M. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000, 283:2404-2410.
66. Verdecchia P., Schillaci G., Reboldi G., Santeusanio F., Porcellati C., Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000, 36:1072-1078.
67. Niskanen L.K., Laaksonen D.E., Nyyssönen K., Alfthan G., Lakka H.M., Lakka T.A., Salonen J.T. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-1551.
68. Witteman J., Breteler M. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006, 37:1503-1507.
69. Sato Y., Yamamoto E., Sawa T., Toda K., Hara T., Iwasaki T., Fujiwara H., Takatsu Y. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol 2011, 58:226-231.
70. Niizeki T., Takeishi Y., Arimoto T., Okuyama H., Nozaki N., Hirono O., Tsunoda Y., Watanabe T., Nitobe J., Miyashita T., Takahashi H., Koyama Y., Kubota I. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 2006, 47:219-228.
71. Niizeki T., Takeishi Y., Kitahara T., Suzuki S., Sasaki T., Ishino M., Kubota I. Combination of conventional biomarkers for risk stratification in chronic heart failure. J Cardiol 2009, 53:179-187.
72. Neogi T., Ellison R.C., Hunt S., Terkeltaub R., Felson D.T., Zhang Y. Serum uric acid is associated with carotid plaques: the National Heart Lung, and Blood Institute Family Heart Study. J Rheumatol 2009, 36:378-384.
73. De Luca G., Secco G.G., Santagostino M., Venegoni L., Iorio S., Cassetti E., Verdoia M., Coppo L., Di Mario C., Bellomo G., Marino P., on behalf of the Novara Atherosclerosis Study Group (NAS) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis December 2010, [Epub ahead of print].
74. Abbott R., Brand F., Kannel W., Castelli W. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988, 41:237-242.
75. Moriarity J., Folsom A., Iribarren C., Nieto F., Rosamond W. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000, 10:136-143.
76. Wannamethee S.G., Shaper A.G., Whincup P.H. Serum urate and the risk of major coronary heart disease events. Heart 1997, 78:147-153.
77. Sakata K., Hashimoto T., Ueshima H., Okayama A., for the NIPPON DATA 80 Research Group Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 2001, 17:461-468.
78. Wheeler J., Juzwishin K., Eiriksdottir G., Gudnason V., Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2:e76.
79. Waring W.S., Webb D.J., Maxwell S.R. Uric acid as a risk factor for cardiovascular disease. Q J Med 2000, 93:707-713.
80. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010, 62:170-180.
81. Pillinger M.H., Goldfarb D.S., Keenan R.T. Gout its comorbidities. Bull NYU Hosp Jt Dis 2010, 68:199-203.
82. Pacher P., Nivorozhkin A., Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006, 58:87-114.
83. Okamoto K., Eger B.T., Nishino T., Kondo S., Pai E.F., Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003, 278:1848-1855.
84. Butler R., Morris A.D., Belch J.J., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
85. Doehner W., Schoene N., Rauchhaus M., Leyva-Leon F., Pavitt D.V., Reaveley D.A., Schuler G., Coats A.J., Anker S.D., Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002, 105:2619-2624.
86. Guthikonda S., Sinkey C., Barenz T., Haynes W.G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003, 107:416-421.
87. George J., Carr E., Davies J., Belch J.J., Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114:2508-2516.
88. Spector T. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol 1988, 37:349-352.
89. Hare J.M., Mangal B., Brown J., Fisher C., Freudenberger R., Colucci W.S., Mann D.L., Liu P., Givertz M.M., Schwarz R.P. OPT-CHF investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51:2301-2309.
90. Wu A.H., Ghali J.K., Neuberg G.W., O'Connor C.M., Carson P.E., Levy W.C. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010, 160:928-933.
91. Baldus S., Müllerleile K., Chumley P., Steven D., Rudolph V., Lund G.K., Staude H.J., Stork A., Köster R., Kähler J., Weiss C., Münzel T., Meinertz T., Freeman B.A., Heitzer T. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med 2006, 41:1282-1288.
92. Ogino K., Kato M., Furuse Y., Kinugasa Y., Ishida K., Osaki S., Kinugawa T., Igawa O., Hisatome I., Shigemasa C., Anker S.D., Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010, 3:73-81.
93. Sakr S.A., Abbas T.M., Amer M.Z., Dawood E.M., El-Shahat N., Abdel Aal I.A., Ramadan M.M. Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction. Int Heart J 2009, 50:407-419.
94. Iribarren C., Folsom A.R., Eckfeldt J.H., McGovern P.G., Nieto F.J. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study Atherosclerosis Risk in Communities. Ann Epidemiol 1996, 6:331-340.
95. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., Tuttle K.R., Rodriguez-Iturbe B., Herrera-Acosta J., Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190.
96. Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75(Suppl. 5):S13-S16.
97. Krishnan E., Baker J.F., Furst D.E., Schumacher H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
98. Panoulas V.F., Douglas K.M., Milionis H.J., Nightingale P., Kita M.D., Klocke R., Metsios G.S., Stavropoulos-Kalinoglou A., Elisaf M.S., Kitas G.D. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens 2008, 22:177-182.
99. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-1821.
100. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
101. Montalcini T., Gorgone G., Gazzaruso C., Sesti G., Perticone F., Pujia A. Relation between serum uric acid and carotid intima media thickness in healthy postmenopausal women. Intern Emerg Med 2007, 2:19-23.
102. Tavil Y., Kaya M.G., Oktar S.O., Sen N., Okyay K., Yazici H.U., Cengel A. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008, 197:159-163.
103. Pacifico L., Cantisani V., Anania C., Bonaiuto E., Martino F., Pascone R., Chiesa C. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009, 160:45-52.
104. Tatli E., Aktoz M., Buyuklu M., Altun A. The relationship between coronary artery disease and uric acid levels in young patients with acute myocardial infarction. Cardiol J 2008, 15:21-25.
105. Dunkelgrun M., Welten G.M., Goei D., Winkel T.A., Schouten O., van Domburg R.T., van Gestel Y.R., Flu W.J., Hoeks S.E., Bax J.J., Poldermans D. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am J Cardiol 2008, 102:797-801.
106. Koton S., Howard S.C., Warlow C.P., Murphy M.F., Rothwell P.M. Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke. Cerebrovasc Dis 2008, 26:517-524.
107. Lazzeri C., Valente S., Chiostri M., Sori A., Bernardo P., Gensini G.F. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. A single center experience. Int J Cardiol 2010, 138:206-209.
108. Schretlen D.J., Inscore A.B., Vannorsdall T.D., Kraut M., Pearlson G.D., Gordon B., Jinnah H.A. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007, 69:1418-1423.
109. Schretlen D.J., Inscore A.B., Jinnah H.A., Rao V., Gordon B., Pearlson G.D. Serum uric acid and cognitive function in community dwelling older adults. Neuropsychology 2007, 21:136-140.
110. Baker J.F., Krishnan E., Chen L., Schumacher H.R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med 2005, 118:816-826.
111. Tsouli S.G., Liberopoulos E.N., Mikhailidis D.P., Athyros V.G., Elisaf M.S. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism 2006, 55:1293-1301.
112. Manzato E. Uric acid: an old actor for a new role. Intern Emerg Med 2007, 2:1-2.